Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Study Identifier
191622-095
CT.gov Identifier
NCT00910845
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • onabotulinumtoxinA
  • normal saline
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months * Inadequate response or limiting side effects with anticholinergics for the treatment of OAB
    Exclusion Criteria:
    * Overactive Bladder caused by neurological condition * Patient has predominance of stress incontinence * History or evidence of pelvic or urological abnormality

    Protocol Summary

    The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.

    Study Locations

    Location
    Status
    Location
    Newport Beach, California, United States
    Status
    Not applicable
    Location
    Victoria, British Columbia, Canada
    Status
    Not applicable